Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Anita Scheuber, MD, PhD
Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors

November 22nd 2024

Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.

FDA
FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors
Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors

November 15th 2024

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

More News

Chemotherapy Regimens in Metastatic NSCLC

Chemotherapy Regimens in Metastatic NSCLC

February 27th 2015
Treating Driver Mutation Negative NSCLC

Treating Driver Mutation Negative NSCLC

February 27th 2015
Novel ALK Inhibitors in NSCLC With Brain Metastases

Novel ALK Inhibitors in NSCLC With Brain Metastases

February 27th 2015
Treatments for ALK-Positive NSCLC

Treatments for ALK-Positive NSCLC

February 27th 2015
ALK Inhibition in NSCLC

ALK Inhibition in NSCLC

February 27th 2015
Types of EGFR Therapy in NSCLC

Types of EGFR Therapy in NSCLC

February 27th 2015
Overcoming EGFR Inhibitor Resistance in NSCLC

Overcoming EGFR Inhibitor Resistance in NSCLC

February 27th 2015
Bevacizumab in Non-Small Cell Lung Cancer

Bevacizumab in Non-Small Cell Lung Cancer

February 27th 2015
First-Line Therapy in EGFR-Mutant Lung Cancer

First-Line Therapy in EGFR-Mutant Lung Cancer

February 27th 2015
Molecular Testing in Non-Small Cell Lung Cancer

Molecular Testing in Non-Small Cell Lung Cancer

February 27th 2015
Future Treatments for Triple-Negative Breast Cancer

Future Treatments for Triple-Negative Breast Cancer

February 25th 2015
Chemotherapeutics for Triple-Negative Breast Cancer

Chemotherapeutics for Triple-Negative Breast Cancer

February 25th 2015
Standard Therapies for Triple-Negative Breast Cancer

Standard Therapies for Triple-Negative Breast Cancer

February 25th 2015
Managing Brain Metastases in Breast Cancer

Managing Brain Metastases in Breast Cancer

February 25th 2015
Role of T-DM1 in HER2-Positive Breast Cancer

Role of T-DM1 in HER2-Positive Breast Cancer

February 25th 2015
Pertuzumab in HER2-Positive Metastatic Breast Cancer

Pertuzumab in HER2-Positive Metastatic Breast Cancer

February 25th 2015
BOLERO-2: Everolimus Plus Exemestane in Resistant MBC

BOLERO-2: Everolimus Plus Exemestane in Resistant MBC

February 25th 2015
Role of Bevacizumab in Breast Cancer

Role of Bevacizumab in Breast Cancer

February 25th 2015
Endocrine Therapy Resistance in Breast Cancer

Endocrine Therapy Resistance in Breast Cancer

February 25th 2015
CDK4/6 Inhibition in Metastatic Breast Cancer

CDK4/6 Inhibition in Metastatic Breast Cancer

February 25th 2015
Treating ER-Positive De Novo Metastatic Breast Cancer

Treating ER-Positive De Novo Metastatic Breast Cancer

February 25th 2015
Genetic Tests Offer New Tool for Tumor Assessment

Genetic Tests Offer New Tool for Tumor Assessment

February 25th 2015
Pathology, Oncology Collaboration in Breast Cancer

Pathology, Oncology Collaboration in Breast Cancer

February 25th 2015
Predicting Risk of Recurrence in Breast Cancer

Predicting Risk of Recurrence in Breast Cancer

February 25th 2015
Reviewing Key Genomic Assays in Breast Cancer

Reviewing Key Genomic Assays in Breast Cancer

February 25th 2015
Pathologist's Role in Genetic Testing for Breast Cancer

Pathologist's Role in Genetic Testing for Breast Cancer

February 25th 2015
Role of Genetic Testing in Breast Cancer

Role of Genetic Testing in Breast Cancer

February 25th 2015
Introduction: Impact of Molecular Subtyping in Breast Cancer

Introduction: Impact of Molecular Subtyping in Breast Cancer

February 25th 2015
Dr. Sotomayor on Precision Medicine for the Prevention of Cancer

Dr. Sotomayor on Precision Medicine for the Prevention of Cancer

February 23rd 2015

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses the future of personalized medicine in lymphoma.

Molecular Analysis Should Guide Treatment Individualization in AML

Molecular Analysis Should Guide Treatment Individualization in AML

February 23rd 2015

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment for patients of acute myeloid leukemia, according to a presentation by Stefan Faderl, MD, at the 2015 International Congress on Hematologic Malignancies.

<1
...
737475767778798081
...
111>